Edibles, Oils, and Vapes FDA's Surprising New Take on Cannabis!

Описание: The FDA has been reviewing applications for cannabis-based therapeutic drugs for over 50 years, coinciding with marijuana's classification as a Schedule I controlled substance. Recently, the FDA published documents reflecting on this history and the evolution of cannabis research, highlighting the increase in investigational new drug applications (INDs) especially in the last decade, which matches the number from the previous four decades.

The FDA has seen a shift in the types of cannabis products being researched, from smokable forms to a variety of other methods including edibles, oils, and vaporized products. This change mirrors the evolving preferences of cannabis consumers in the U.S. who have moved from smoking dried cannabis flower to consuming a range of non-flower forms.

The agency acknowledges the challenges in researching cannabis due to its Schedule I status, which imposes stringent regulations and limits studies. However, there have been some advancements, such as the DEA ending its monopoly on marijuana manufacturing for research and reviewing the scheduling status of marijuana.

The FDA continues to support scientific research into cannabis and its components, like lesser-known cannabinoids and terpenes, and is working to facilitate the development of new drugs through the IND and drug approval processes. Despite the complex legal and regulatory landscape, the FDA is committed to supporting the therapeutic uses of cannabis and cannabis-derived products.

FDA, cannabis research, marijuana, drug development, terpenes, edibles, Schedule I, clinical trials, cannabinoids

(https://www.facebook.com/groups/StonersHip...) - ✌🏿 Community of weed enthusiasts, by weed enthusiasts.